Krishnamoorthy et al. 2019 (PRJNA453686)

General Details

Title EIF1AX-A113 splice and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC
Organism
Number of Samples 6
Release Date 2018/04/26 00:00
Sequencing Types
Protocol Details

Study Links

Repository Details

SRA SRP142722
ENA SRP142722
GEO
BioProject PRJNA453686

Publication

Title
Authors Krishnamoorthy GP,Davidson NR,Leach SD,Zhao Z,Lowe SW,Lee G,Landa I,Nagarajah J,Saqcena M,Singh K,Wendel HG,Dogan S,Tamarapu PP,Blenis J,Ghossein RA,Knauf JA,Rätsch G,Fagin JA
Journal Cancer discovery
Publication Date 2019 Feb
Abstract Translation initiation is orchestrated by the cap binding and 43S preinitiation complexes (PIC). Eukaryotic initiation factor 1A (EIF1A) is essential for recruitment of the ternary complex and for assembling the 43S PIC. Recurrent EIF1AX mutations in papillary thyroid cancers are mutually exclusive with other drivers, including RAS . EIF1AX mutations are enriched in advanced thyroid cancers, where they display a striking co-occurrence with RAS , which cooperates to induce tumorigenesis in mice and isogenic cell lines. The C-terminal EIF1AX-A113splice mutation is the most prevalent in advanced thyroid cancer. EIF1AX-A113splice variants stabilize the PIC and induce ATF4, a sensor of cellular stress, which is co-opted to suppress EIF2α phosphorylation, enabling a general increase in protein synthesis. RAS stabilizes c-MYC, an effect augmented by EIF1AX-A113splice. ATF4 and c-MYC induce expression of amino acid transporters and enhance sensitivity of mTOR to amino acid supply. These mutually reinforcing events generate therapeutic vulnerabilities to MEK, BRD4, and mTOR kinase inhibitors. SIGNIFICANCE: Mutations of EIF1AX, a component of the translation PIC, co-occur with RAS in advanced thyroid cancers and promote tumorigenesis. EIF1AX-A113splice drives an ATF4-induced dephosphorylation of EIF2α, resulting in increased protein synthesis. ATF4 also cooperates with c-MYC to sensitize mTOR to amino acid supply, thus generating vulnerability to mTOR kinase inhibitors. This article is highlighted in the In This Issue feature, p. 151 . ©2018 American Association for Cancer Research.
PMC PMC6373451
PMID 30305285
DOI
Run Accession Study Accession Scientific Name Cell Line Library Type Treatment GWIPS-viz Trips-Viz Reads BAM BigWig (F) BigWig (R)
SRR7067554 PRJNA453686 Homo sapiens C643 Ribo-Seq Cycloheximide
SRR7067555 PRJNA453686 Homo sapiens C643 Ribo-Seq Cycloheximide
SRR7067556 PRJNA453686 Homo sapiens C643 Ribo-Seq Cycloheximide
SRR7067557 PRJNA453686 Homo sapiens C643 Ribo-Seq Cycloheximide
SRR7067558 PRJNA453686 Homo sapiens C643 Ribo-Seq Cycloheximide
SRR7067559 PRJNA453686 Homo sapiens C643 Ribo-Seq Cycloheximide
Run Accession Study Accession Scientific Name Cell Line Library Type Treatment GWIPS-viz Trips-Viz Reads BAM BigWig (F) BigWig (R)

ⓘ For more Information on the columns shown here see: About